(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
Live Chart Being Loaded With Signals
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer...
Stats | |
---|---|
Today's Volume | 375.00 |
Average Volume | 23 677.00 |
Market Cap | 91.54M |
EPS | $0 ( 2024-05-10 ) |
Next earnings date | ( $-0.500 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.0310 (1.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-10 | Dawes Karen A | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Scheeren Joseph | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Phillips Anne M. | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Hammacher Alex | Buy | 19 516 | Share Option (Right to Buy) |
2024-05-10 | Morgon Pierre A. | Buy | 19 516 | Share Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 6 transactions |
Buy: 117 096 | Sell: 0 |
Barinthus Biotherapeutics Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Barinthus Biotherapeutics Financials
Annual | 2023 |
Revenue: | $805 108 |
Gross Profit: | $802 000 (99.61 %) |
EPS: | $-1.920 |
FY | 2023 |
Revenue: | $805 108 |
Gross Profit: | $802 000 (99.61 %) |
EPS: | $-1.920 |
FY | 2022 |
Revenue: | $44.70M |
Gross Profit: | $44.70M (100.00 %) |
EPS: | $0.140 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators